{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:16:12Z","timestamp":1791033372371,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T00:00:00Z","timestamp":1240358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s00108-009-2388-9","type":"journal-article","created":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T20:15:07Z","timestamp":1240258507000},"page":"617-626","source":"Crossref","is-referenced-by-count":3,"title":["Nobelpreis f\u00fcr die Impfung gegen Zervixkrebs","Nobel price for vaccination against cervical cancer: Current data and guidelines"],"prefix":"10.1007","volume":"50","author":[{"given":"H.M.","family":"Hepburn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,22]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","volume":"369","author":"Ault","year":"2007","unstructured":"Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861\u20131868","journal-title":"Lancet"},{"key":"2388_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/jmbi.1998.1920","volume":"281","author":"Booy","year":"1998","unstructured":"Booy FP, Roden RB, Greenstone HL et al. (1998) Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J Mol Biol 281: 95\u2013106","journal-title":"J Mol Biol"},{"key":"2388_CR3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/j.1460-2075.1984.tb01944.x","volume":"3","author":"Boshart","year":"1984","unstructured":"Boshart M, Gissmann L, Ikenberg H et al. (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 3: 1151\u20131157","journal-title":"EMBO J"},{"key":"2388_CR4","doi-asserted-by":"crossref","unstructured":"David MP, Van Herck K, Hardt K et al. (2009) Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol [Epub ahead of print]","DOI":"10.1016\/j.ygyno.2009.01.011"},{"key":"2388_CR5","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","volume":"80","author":"Durst","year":"1983","unstructured":"Durst M, Gissmann L, Ikenberg H, Zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 80: 3812\u20133815","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2388_CR6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"FUTURE","year":"2007","unstructured":"FUTURE II (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915\u20131927","journal-title":"N Engl J Med"},{"key":"2388_CR7","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928\u20131943","journal-title":"N Engl J Med"},{"key":"2388_CR8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/CVI.00478-06","volume":"14","author":"Garland","year":"2007","unstructured":"Garland SM, Steben M, Hernandez-Avila M et al. (2007) Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 14: 792\u2013795","journal-title":"Clin Vaccine Immunol"},{"key":"2388_CR9","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","volume":"24","author":"Giannini","year":"2006","unstructured":"Giannini SL, Hanon E, Moris P et al. (2006) Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24: 5937\u20135949","journal-title":"Vaccine"},{"key":"2388_CR10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"Harper","year":"2004","unstructured":"Harper DM, Franco EL, Wheeler C et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757\u20131765","journal-title":"Lancet"},{"key":"2388_CR11","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247\u20131255","journal-title":"Lancet"},{"key":"2388_CR12","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","volume":"369","author":"Joura","year":"2007","unstructured":"Joura EA, Leodolter S, Hernandez-Avila M et al. (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369: 1693\u20131702","journal-title":"Lancet"},{"key":"2388_CR13","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","volume":"97","author":"Khan","year":"2005","unstructured":"Khan MJ, Castle PE, Lorincz AT et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072\u20131079","journal-title":"J Natl Cancer Inst"},{"key":"2388_CR14","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","volume":"89","author":"Kirnbauer","year":"1992","unstructured":"Kirnbauer R, Booy F, Cheng N et al. (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89: 12180\u201312184","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2388_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","volume":"102","author":"Koutsky","year":"1997","unstructured":"Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102: 3\u20138","journal-title":"Am J Med"},{"key":"2388_CR16","unstructured":"Luther-\u00dcbersetzung (1545) Die Bibel, 5. Buch Mose. Kap. 28, Vers 27"},{"key":"2388_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","volume":"9","author":"McCredie","year":"2008","unstructured":"McCredie MR, Sharples KJ, Paul C et al. (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9: 425\u2013434","journal-title":"Lancet Oncol"},{"key":"2388_CR18","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch FX et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161\u20132170","journal-title":"Lancet"},{"key":"2388_CR19","first-page":"120","volume":"17","author":"Pathirana","year":"2008","unstructured":"Pathirana D, f\u00fcr das HPV Management Forum (2008) S3-Leitlinie zur Impfpr\u00e4vention HPV-assoziierter Neoplasien. J Chemother 17: 120\u2013171","journal-title":"J Chemother"},{"key":"2388_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","volume":"26","author":"Reisinger","year":"2007","unstructured":"Reisinger KS, Block SL, Lazcano-Ponce E et al. (2007) Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26: 201\u2013209","journal-title":"Pediatr Infect Dis J"},{"key":"2388_CR21","first-page":"97","volume":"12","author":"Robert","year":"2007","unstructured":"Robert Koch-Institut (2007) Mittteilung der St\u00e4ndigen Impfkommission (STIKO) am Robert-Koch-Institut. Impfung gegen humane Papillomaviren (HPV) f\u00fcr M\u00e4dchen von 12 bis 17 Jahren \u2013 Empfehlung und Begr\u00fcndung. Epidemiol Bull 12: 97\u2013103","journal-title":"Epidemiol Bull"},{"key":"2388_CR22","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","volume":"26","author":"Schiller","year":"2008","unstructured":"Schiller JT, Castellsague X, Villa LL, Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 (Suppl): K53\u2013K61","journal-title":"Vaccine"},{"key":"2388_CR23","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1055\/s-2007-991634","volume":"132","author":"Schreckenberger","year":"2007","unstructured":"Schreckenberger C, Kaufmann AM, Schneider A (2007) Implementation of HPV vaccination in Germany. Dtsch Med Wochenschr 132: 2221\u20132224","journal-title":"Dtsch Med Wochenschr"},{"key":"2388_CR24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/INF.0b013e318149dfea","volume":"26","author":"Siegrist","year":"2007","unstructured":"Siegrist CA, Lewis EM, Eskola J et al. (2007) Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 26: 979\u2013984","journal-title":"Pediatr Infect Dis J"},{"key":"2388_CR25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4161\/hv.3.4.4058","volume":"3","author":"Smith","year":"2007","unstructured":"Smith JF, Brownlow M, Brown M et al. (2007) Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 3: 109\u2013115","journal-title":"Hum Vaccin"},{"key":"2388_CR26","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","volume":"24","author":"Villa","year":"2006","unstructured":"Villa LL, Ault KA, Giuliano AR et al. (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24: 5571\u20135583","journal-title":"Vaccine"},{"key":"2388_CR27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"Villa","year":"2006","unstructured":"Villa LL, Costa RL, Petta CA et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459\u20131466","journal-title":"Br J Cancer"},{"key":"2388_CR28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijc.2910330111","volume":"33","author":"Vonka","year":"1984","unstructured":"Vonka V, Kanka J, Hirsch I et al. (1984) Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrolment. Int J Cancer 33: 61\u201366","journal-title":"Int J Cancer"},{"key":"2388_CR29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ijc.2910330110","volume":"33","author":"Vonka","year":"1984","unstructured":"Vonka V, Kanka J, Jelinek J et al. (1984) Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer 33: 49\u201360","journal-title":"Int J Cancer"},{"key":"2388_CR30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","volume":"26","author":"Wheeler","year":"2008","unstructured":"Wheeler CM, Bautista OM, Tomassini JE et al. (2008) Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26: 686\u2013696","journal-title":"Vaccine"},{"key":"2388_CR31","first-page":"794","volume":"36","author":"Zur","year":"1976","unstructured":"Zur Hausen H (1976) Condylomata acuminata and human genital cancer. Cancer Res 36: 794","journal-title":"Cancer Res"},{"key":"2388_CR32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","volume":"2","author":"Zur","year":"2002","unstructured":"Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342\u2013350","journal-title":"Nat Rev Cancer"},{"key":"2388_CR33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","volume":"384","author":"Zur","year":"2009","unstructured":"Zur Hausen H (2009) Papillomaviruses in the causation of human cancers \u2013 a brief historical account. Virology 384: 260\u2013265","journal-title":"Virology"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-009-2388-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-009-2388-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-009-2388-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:12:13Z","timestamp":1558584733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-009-2388-9"}},"subtitle":["Aktuelle Daten- und Leitlinienlage"],"short-title":[],"issued":{"date-parts":[[2009,4,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1007\/s00108-009-2388-9","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,22]]}}}